Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 13/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | PRKCA | P17252 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 12/20 | 0.53 |
| ▸ | CA1 | P00915 | 12/20 | 0.53 |
| ▸ | CA9 | Q16790 | 12/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14365714 | 1.00 | CYP2D6 (0.66) | CYP2D6THRBHSD17B10CA2NR3C1 | |
| SCHEMBL12157410 | 1.00 | CYP2D6 (0.66) | CYP2D6THRBHSD17B10CA2NR3C1 | |
| SCHEMBL1582595 | 1.00 | CYP2D6 (0.66) | CYP2D6THRBHSD17B10CA2NR3C1 | |
| SCHEMBL1582431 | 1.00 | CYP2D6 (0.66) | CYP2D6THRBHSD17B10CA2NR3C1 | |
| SCHEMBL13655911 | 1.00 | CYP2D6 (0.66) | CYP2D6THRBHSD17B10CA2NR3C1 | |
| SCHEMBL61751 | 1.00 | CYP2D6 (0.66) | CYP2D6THRBHSD17B10CA2NR3C1 | |
| SCHEMBL10520478 | 1.00 | CYP2D6 (0.66) | CYP2D6THRBHSD17B10CA2NR3C1 | |
| SCHEMBL13362481 | 1.00 | CYP2D6 (0.66) | CYP2D6THRBHSD17B10CA2NR3C1 | |
| SCHEMBL21750083 | 1.00 | CYP2D6 (0.66) | CYP2D6THRBHSD17B10CA2NR3C1 | |
| SCHEMBL21750089 | 1.00 | CYP2D6 (0.66) | CYP2D6THRBHSD17B10CA2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1045 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117677211-A | Cellulose ester derivative passivation layer solar cell and preparation method thereof | 福建农林大学 | 2024-03-08 | — | — | CN | claimed |
| US-20220331289-A1 | Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery | CIPLA LIMITED (IN) | 2022-10-20 | — | — | US | claimed |
| US-20190151453-A1 | Drug/polymer Composite Materials And Methods Of Making The Same | MICELL TECHNOLOGIES, INC. (US) | 2019-05-23 | — | — | US | claimed |
| US-20170326102-A1 | Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery | CIPLA LIMITED (IN) | 2017-11-16 | — | — | US | claimed |
| WO-2016083827-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ARTEMISININ DERIVATIVE FOR NASAL OR PULMONARY DELIVERY | CIPLA LIMITED (IN) | 2016-06-02 | — | — | WO | claimed |
| CN-102247597-B | Novel inhalant containing glucocorticoid and bronchodilator | TIANJIN JINYAO GROUP CO LTD | 2015-01-07 | — | — | CN | claimed |
| US-20100329996-A1 | Novel Combination of Therapeutic Agents | GLAXO GROUP LIMITED | 2010-12-30 | — | — | US | claimed |
| CN-101801378-A | Novel combination of therapeutic agents | GLAXO GROUP LTD | 2010-08-11 | — | — | CN | claimed |
| EP-2197444-A1 | NOVEL COMBINATION OF THERAPEUTIC AGENTS | Glaxo Group Limited (GB) | 2010-06-23 | — | — | EP | claimed |
| WO-2009036243-A1 | NOVEL COMBINATION OF THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | WO | claimed |
| WO-2001003673-A1 | DRY POWDER COMPOSITIONS | QUADRANT HEALTHCARE (UK) LIMITED (GB) | 2001-01-18 | — | — | WO | claimed |
| CN-1242702-A | Methods and compositions for increasing bioavailability of bioactive agents delivered through mucosa | QUADRANT HOLDINGS CAMBRIDGE (GB) | 2000-01-26 | — | — | CN | claimed |
| EP-0949907-A1 | METHODS AND COMPOSITIONS FOR IMPROVED BIOAVAILABILITY OF BIOACTIVE AGENTS FOR MUCOSAL DELIVERY | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 1999-10-20 | — | — | EP | claimed |
| CN-1204959-A | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same | QUADRANT HOLDINGS CAMBERIDGE L (GB) | 1999-01-13 | — | — | CN | claimed |
| WO-1998029097-A1 | METHODS AND COMPOSITIONS FOR IMPROVED BIOAVAILABILITY OF BIOACTIVE AGENTS FOR MUCOSAL DELIVERY | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 1998-07-09 | — | — | WO | claimed |
| EP-0773781-A1 | SOLID DELIVERY SYSTEMS FOR CONTROLLED RELEASE OF MOLECULES INCORPORATED THEREIN AND METHODS OF MAKING SAME | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 1997-05-21 | — | — | EP | claimed |
| WO-1996003978-A1 | SOLID DELIVERY SYSTEMS FOR CONTROLLED RELEASE OF MOLECULES INCORPORATED THEREIN AND METHODS OF MAKING SAME | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 1996-02-15 | — | — | WO | claimed |
| EP-0159431-B1 | TIGOGENIN-CELLOBIOSIDE AND ITS HEPTAACETATE, METHODS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING TIGOGENIN-CELLOBIOSIDE | MEDICAL RESEARCH FOUNDATION OF OREGON (US) | 1989-05-10 | — | — | EP | claimed |
| US-4797361-A | CULTURE TO PRODUCE ENZYMES, TRICHODERMA PRODUCES PROTEASE | LEHIGH UNIVERSITY (US) | 1989-01-10 | — | — | US | claimed |
| EP-0159431-A2 | Tigogenin-cellobioside and its heptaacetate, methods for their preparation, and pharmaceutical compositions containing tigogenin-cellobioside | MEDICAL RESEARCH FOUNDATION OF OREGON (US) | 1985-10-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331289-A1 | Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery | DIAPH1, DHPS, SQLE | CYP2D6 154/4885THRB 4834/4885HSD17B10 1241/4885 |
| US-20100329996-A1 | Novel Combination of Therapeutic Agents | CHRNB1, CHRM3, CHRNB2 | CYP2D6 4370/4885THRB 71/4885HSD17B10 3135/4885 |
| US-20170326102-A1 | Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery | DIAPH1, DHPS, SQLE | CYP2D6 154/4885THRB 4834/4885HSD17B10 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.